| Identification | Back Directory | [Name]
Paquinimod | [CAS]
248282-01-1 | [Synonyms]
ABR25757
ABR-25757
ABR 25757
ABR?215757
Paquinimod
ABR?215757; ABR 215757; ABR215757; PAQUINIMOD.
ABR 25757;ABR-25757;ABR25757;PAQUINIMOD;248282-01-1
N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
3-Quinolinecarboxamide, N,5-diethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl- | [Molecular Formula]
C21H22N2O3 | [MDL Number]
MFCD18633277 | [MOL File]
248282-01-1.mol | [Molecular Weight]
350.41 |
| Chemical Properties | Back Directory | [Boiling point ]
487.3±45.0 °C(Predicted) | [density ]
1.267±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO:15.0(Max Conc. mg/mL);42.8(Max Conc. mM) | [form ]
A solid | [pka]
4.50±1.00(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Paquinimod is a S100A9 inhibitor preventing S100A9 binding to TLR-4. Paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Paquinimod treatment of collagenase-induced OA (CIOA) resulted in significantly reduced synovial thickening (57%), osteophyte size at the medial femur (66%) and cruciate ligaments (67%) and cartilage damage at the medial tibia (47%) and femur (75%; n=7, untreated n=6). Paquinimod reduces leukocyte recruitment during sterile inflammation. Paquinimod also reduced priming of proinflammatory effector CD4(+) T cells. |
|
| Company Name: |
ChemCell Biomedicine Co.,Ltd.
|
| Tel: |
020-13556033878 2965585218 13556033878 |
| Website: |
http://www.approvedhomemanagement.com/ShowSupplierProductsList15061/0.htm |
|